<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Public Health]]></title>
    <link>https://www.leadingmarketresearch.com/healthcare/public-health</link>
    <description><![CDATA[Public Health]]></description>
    <pubDate>Wed, 22 Apr 2026 19:16:49 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Temple University - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/temple-university-pharmaceuticals-and-healthcare-deals-and-alliances</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Temple University (Temple) is an educational and research university that offers undergraduate and graduate courses. The university offers undergraduate courses in various fields such as arts, media and communication, medicine, engineering, pharmacy and others. Temple offers its degree programs through schools and colleges such as Tyler School of Art, Fox School of Business and Management, Maurice H. Kornberg School of Dentistry School of Medicine, Boyer College of Music and Dance, School of Pharmacy and Temple school of Pharmacy, among others. The university has campuses in Rome and Tokyo, and offers programs in London, China, Korea, Greece, Israel, and others. Temple is located in Philadelphia, Pennsylvania, the US.<br><br>Temple University - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188010"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[TCG Lifesciences Ltd - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/tcg-lifesciences-ltd-pharmaceuticals-and-healthcare-deals-and-allianc</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>TCG Lifesciences Ltd (TCG Lifesciences), formerly Chembiotek Research International Private Limited is a subsidiary of TCG Digital Solutions LLC, contract research service provider that offers research services in the areas of drug discovery and drug development to pharma and biotechnology companies. The company offers chemistry and preclinical discovery services including medicinal chemistry synthesis, process research and development, cGMP kilo scale synthesis, in-vivo pharmacology, genetic toxicology, genotyping, gene sequencing, medical writing, drug metabolism and pharmacokinetics, among others. It provides technology platforms for field potential recording, conventional patch clamp and automated patch clamp. The company has its presence in India, Europe, Japan, Australia and the US. TCG Lifesciences is headquartered in Kolkata, West Bengal, India.<br><br>TCG Lifesciences Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships a...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188025"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Sound Pharmaceuticals Inc - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/sound-pharmaceuticals-inc-pharmaceuticals-and-healthcare-deals-and-al</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Sound Pharmaceuticals Inc (SPI) is an independent biopharmaceutical company that focuses on the development of therapeutics for sensorineural otologic diseases. Its products portfolio comprises SPI-1005, SPI-3005 and SPI-5557. It offer products for treatment of meniere’s disease, sensorineural diseases of the inner ear, noise induced hearing loss, tinnitus, and age-related hearing loss (presbycusis) among others. The company’s SPI-3005 is a chemoprotection for tinnitus; and SPI-5557 is used for regeneration of deaf. It focuses on developing drugs to regenerate cells within the cochlea and restore hearing, for individuals with severe to profound hearing loss.SPI is headquartered in Seattle, Washington, the US.<br><br>Sound Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188067"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Synergy Pharmaceuticals Inc (SGYP) - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/synergy-pharmaceuticals-inc-sgyp-pharmaceuticals-and-healthcare-dea</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Synergy Pharmaceuticals Inc (Synergy Pharma), a subsidiary of Pawfect Foods Inc, develops therapies for gastrointestinal (GI) diseases using its proprietary GI platform, which is based on uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company concentrates in therapeutic areas such as chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and ulcerative colitis (UC). Synergy Pharma’s product portfolio includes plecanatide (SP-304), a drug candidate, which is used to treat CIC and IBS-C; and dolcanatide (SP-333) for the treatment of OIC and UC. The company develops product based on the natural human hormone. It has a research center in Philadelphia. Synergy Pharma is headquartered in New York, the US.<br><br>Synergy Pharmaceuticals Inc (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188072"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[University of Strathclyde - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/university-of-strathclyde-pharmaceuticals-and-healthcare-deals-and-al</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>University of Strathclyde (Strathclyde) is an educational research university that provides students with quality education, innovative teaching, learning technologies and facilities. The university offers a wide range of undergraduate and postgraduate programmes, and distance learning programmes through its four faculties such as Faculty of Engineering, Faculty of Science, Humanities and Social Sciences, and the Strathclyde Business School. It has a portfolio of international research contracts to sustain improvements in the fields of medicine, environment, energy and physics. The university also has collaborative agreements with institutions, universities and businesses in over 50 countries. Strathclyde is headquartered in Glasgow, the UK.<br><br>University of Strathclyde - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, P...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188087"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[University of Texas Southwestern Medical Center - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/university-of-texas-southwestern-medical-center-pharmaceuticals-and-hea</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>University of Texas Southwestern Medical Center (UTSMC), a subsidiary of University of Texas System, is an educational service provider that offers undergraduate, graduate, and research programs to physicians, biomedical scientists, and other healthcare professionals. It offers degree programs, which include Master&#039;s Degree in Business Administration, Master&#039;s Degree in Public Health, Medical Scientist Training Program and Bachelor of Arts in Biology. UTSMC offers training programs in various fields. The university carries out research activities in the areas of oncology, diabetes, obesity, cardiology, metabolism and nutrition, trauma and others. It operates through its academic medical centers, patient care providers and research institutions. UTSMC is headquartered in Dallas, Texas, the US.<br><br>University of Texas Southwestern Medical Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188092"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[University of Manchester - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/university-of-manchester-pharmaceuticals-and-healthcare-deals-and-all</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>University of Manchester (UOM) is an educational and research institution that offers undergraduate, and post graduate master’s programs. The university offers courses in accounting and finance; aerospace engineering; computer science; cognitive neuroscience and psychology; economics; learning disability; modern languages and cultures; and psychology; among others. It has over various academic schools and academic and research staff. UOM is a part of Russell Group of universities. The university was a merger of Victoria University of Manchester and the University of Manchester Institute of Science and Technology. It is a member of Universities Research Association group. University of Manchester is headquartered in Manchester, the UK.<br><br>University of Manchester - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188093"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[The Wistar Institute - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/the-wistar-institute-pharmaceuticals-and-healthcare-deals-and-allianc</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>The Wistar Institute (Wistar) is an independent nonprofit biomedical research institute that carries out medical research and training in cancer, infectious diseases, immunology and vaccine development. The institute conducts research on genes, gene expression, and DNA biology; cancer biology; translational research; and virology. Wistar is involved in the development of vaccines against rotavirus, rabies, and rubella; the identification of genes associated with breast, lung, prostate and other cancers; and the development of monoclonal antibodies and other research technologies and tools. It offers postdoctoral, predoctoral, and high school programs in biomedical research. The institute works in partnership with University of Pennsylvania, Children’s Hospital of Philadelphia, and Temple University and other research organizations. Wistar is headquartered in Philadelphia, Pennsylvania, the US.<br><br>The Wistar Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Merg...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188134"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[TAP Biosystems Ltd - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/tap-biosystems-ltd-pharmaceuticals-and-healthcare-deals-and-alliances</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>TAP Biosystems Ltd (TAP), a subsidiary of Sartorius Stedim Biotech GmbH is a medical laboratory that provides laboratory and pharmaceutical equipment. The laboratory offers products such as single-use mini bioreactor systems and automated cell culture systems. It also provides labware, consumables and accessories. TAP offers services including installation, onsite repair services, preventative maintenance, operator and maintenance training, system and software upgrades, lab relocations and decommissioning, protocol development, and validation and GMP compliance. The laboratory’s products are used for drug discovery, biologics production, bioprocess development, regenerative medicine and tissue engineering. It partners with distribution companies. The laboratory operates in Royston, the UK; and Wilmington, the US. TAP is headquartered in Royston, the UK.<br><br>TAP Biosystems Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships a...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188136"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Valeant Canada Ltd - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/valeant-canada-ltd-pharmaceuticals-and-healthcare-deals-and-alliances</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Valeant Canada Ltd (Valeant Canada), a subsidiary of Valeant Pharmaceuticals International Inc, is a pharmaceutical company that develops, manufactures and markets pharmaceutical products. The company’s products include aczone, aldara, benzaclin, biacna, dermatix ultra, dermatop, dermatop II, efudex, elidel, glumetza, lodalis, loprox, nitoman, noritate, ovita, penlac, perlane, ralivia, restylane, restylane-L, retin-A, retin-A micro and sculptra, among others. Its products find application in therapeutic areas of pain management, cardiovascular disease, neurology and dermatology. Valeant Canada serves pharmacies, healthcare practices and hospitals. Valeant Canada operates its manufacturing facilities in Manitoba, Ontario and Quebec, Canada. The company has its presence in the US and Canada. Valeant Canada is headquartered in Laval, Quebec, Canada.<br><br>Valeant Canada Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and fina...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188143"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[One Call Care Management Inc - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/one-call-care-management-inc-pharmaceuticals-and-healthcare-deals-and</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>One Call Care Management Inc (OCCM), formerly One Call Medical, Inc. is a healthcare technology company that develops and markets solutions to the workers’ compensation industry. The company offers software solutions for diagnostics management software, dental + doctor program, transport and translate system, and equipment and device management system. It provides connections within the transportation and language services, diagnostics, home and complex care management, dental and other medical specialties. The company&#039;s dental + doctor services assists dentists and specialty providers in generating revenue, getting payment and navigating the workers’ compensation, auto and liability claims industry. It has operations in Jacksonville, Parsippany, West Hills, Alpharetta and Tampa, the US. OCCM is headquartered in Jacksonville, Florida, the US.<br><br>One Call Care Management Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partners...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188146"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Sunovion Respiratory Development Inc - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/sunovion-respiratory-development-inc-pharmaceuticals-and-healthcare-d</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Sunovion Respiratory Development Inc (Sunovion), a subsidiary of Sunovion Pharmaceuticals Inc is a biopharmaceutical company that develops, manufactures, markets and distributes aerosol or inhaled drug products and therapies for patients with respiratory diseases. The company’s products include eszopiclone, lurasidone HCl, levalbuterol HCl, levalbuterol tartrate, arformoterol tartrate and ciclesonide. Sunovion’s products are used in the treatment of schizophrenia, bipolar depression, insomnia, epilepsy, asthma, allergies and COPD. It also has collaboration with outside partners on various corporate development and licensing arrangements. The company has operations in the US and Canada. Sunovion is headquartered in Marlborough, Massachusetts, the US.<br><br>Sunovion Respiratory Development Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, E...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188152"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[TRPHARM Ilac Sanayi Tic AS - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/trpharm-ilac-sanayi-tic-as-pharmaceuticals-and-healthcare-deals-and-a</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>TRPHARM Ilac Sanayi Tic AS (TR-Pharm) is a research and development based pharmaceutical company that provides alternative solutions in certain treatment areas to patients and healthcare professionals. The company offers a wide range of products in therapeutic areas such as virology, inflammatory diseases, oncology, and other rare diseases. It develops six products for the treatment of cancer such as RPH-001, RPH-002, RPH-203, RPH-112, RPH-114, and RPH-120. Its pipeline products in the area of inflammatory diseases include RPH-104 and RPH-113. The company has partnerships with pharmaceutical companies. TR-Pharm is headquartered in Istanbul, Turkey.<br><br>TRPHARM Ilac Sanayi Tic AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a f...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188178"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Thrive Bioscience Inc - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/thrive-bioscience-inc-pharmaceuticals-and-healthcare-deals-and-allian</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Thrive Bioscience Inc (Thrive Bioscience) is a development stage life science analytical and automation technology company. It focuses on the development of cell structure instruments based on the analytical and automation technology for life science companies. The company’s innovative systems provide the reproducible protocols, scalable cell propagation, analytics and complete process history documentation with the images. Thrive Bioscience’s systems provide interaction between cell biologists and technicians to maintain and manipulate the cells. The company’s systems help to remove the causes of variation inherent in manual cell culture. It is a spin-off of Sage Science, Inc. Thrive Bioscience is headquartered in Beverly, Massachusetts, the US.<br><br>Thrive Bioscience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offer...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188179"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[VCN Biosciences SL - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/vcn-biosciences-sl-pharmaceuticals-and-healthcare-deals-and-alliances</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>VCN Biosciences SL (VCN) is a biotechnology company that develops tumor therapeutics. The company offers VCN-01, a tumor-selective replication-competent adenovirus expressing PH20 hyaluronidase, a glycosylphosphatidylinositol-anchored enzyme that degrades hyaluronan, and structural elements of tumor extracellular matrix. It uses oncolytic adenovirus technology platform to design selective and efficient agents that replicate and self-amplify in tumor cells. VCN aims to develop agents for the treatment of cancer based on oncolytic adenoviruses with high potency and selectivity. The company also develops new candidate viruses from its design, preclinical studies, and early efficacy studies in humans. VCN is headquartered in Sant Cugat del Valles, Spain.<br><br>VCN Biosciences SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings,...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188193"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[TFS International AB - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/tfs-international-ab-pharmaceuticals-and-healthcare-deals-and-allianc-191316</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>TFS International AB (TFS International) is a contract research organization that offers clinical development solutions. The organization through its business areas, TFS Develop and TFS People, provides various services worldwide including clinical development planning, regulatory affairs, feasibility, study and site coordination, patient recruitment services, clinical data management, biostatistics, pharmacovigilance and safety, medical writing, training, quality assurance, functional service solutions and others. Its core therapeutic areas include oncology, cardiovascular, dermatology, immunology, CNS, endocrinology and ophthalmology. The organization operates through regional and sales offices in Europe, Americas and others. TFS International is headquartered in Lund, Sweden.<br><br>TFS International AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acqui...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188195"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Tarveda Therapeutics Inc - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/tarveda-therapeutics-inc-pharmaceuticals-and-healthcare-deals-and-all</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Tarveda Therapeutics Inc (Tarveda), formerly Blend Therapeutics, Inc., is a biopharmaceutical company that discovers and develops miniaturized novel biologic drug conjugates to target, penetrate and treat solid tumors. The company develops two distinct classes of targeted anti-cancer medicines for advancing the treatment for solid tumors. Pipeline portfolio of Tarveda includes its lead drug candidate, BTP-114, a novel, personalized cisplatin prodrug and BTP-277 and other novel drug conjugates from the company’s proprietary Pentarin platform. It collaborates with other pharmaceutical companies to develop either its proprietary Pentarins or new miniaturized biologic drug conjugates; or miniaturized biologic drug conjugate. Tarveda is headquartered in Watertown, Massachusetts, the US.<br><br>Tarveda Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188222"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Theravectys SA - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/theravectys-sa-pharmaceuticals-and-healthcare-deals-and-alliances-pro</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Theravectys SA (TheraVectys) is a biotechnology company that develops new generation of therapeutic vaccines and immunotherapies. The company develops vaccine platform for the treatment and prevention of infectious diseases, cancers, and other diseases and conditions. It is developing therapeutic vaccine against HIV, which is undergoing the phase I/II clinical trial. TheraVectys conducts research and development activities at the Pasteur Institute. The company partners with other biotech companies to develop its lentiviral vector platform for the discovery of therapies for its oncology and infectious diseases. Theravectys is headquartered in Villejuif, France.<br><br>Theravectys SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a f...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188240"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Twist Bioscience Corp - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/twist-bioscience-corp-pharmaceuticals-and-healthcare-deals-and-allian</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Twist Bioscience Corp (Twist Bioscience) specializes in the development of synthetic DNA. The company’s products includes DNA pools for gRNA cloning such as unamplified oligo pools, cloning-ready oligo pools; protein scanning single variant libraries, clonal perfect genes and non-clonal fragments among others. Twist Bioscience uses synthetic DNA for targeted resequencing, virus, pathogens, metagenomics, non-coding DNA, pathogen mode of action, RNA editing, gene synthesis, genome synthesis, biofuel and chemical production, directed evolution, antibodies,  vaccines, shRNA, antibiotics and data storage. The company is funded by ARCH Venture Partners and Paladin Capital Group. Twist Bioscience is headquartered in San Francisco, California, the US.<br><br>Twist Bioscience Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, P...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188261"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Transgenomic Inc (TBIO) - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/transgenomic-inc-tbio-pharmaceuticals-and-healthcare-deals-and-alli</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Transgenomic Inc (Transgenomic) is a biotechnology company that offers personalized medicine in oncology, cardiology, neurology, and inherited diseases. The company’s products include ICEme Kits, and genetic assays and platforms. Its offers genetic assays and platforms such as chromatography, hanabi cytogenetic systems, genetic analysis kits, PCR reagents, tissue microarray platforms and WAVE DHPLC systems. Transgenomic provides specimen collection kits which include cardiology kits, neurology kits, oncology kits, pharmacogenomic kits, scoliscore AIS prognostic kits and Whole Exome sequencing kits. The company offers patient testing services for cardiology, neurology, mitochondrial disorders and oncology. Transgenomic is headquartered in Omaha, Nebraska, the US.<br><br>Transgenomic Inc (TBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188273"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[OncoSil Medical Ltd (OSL) - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/oncosil-medical-ltd-osl-pharmaceuticals-and-healthcare-deals-and-al</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>OncoSil Medical Ltd (OncoSil), formerly NeuroDiscovery Limited is a biotechnology company that develops and commercializes products for the neurology market. The company offers products such as NDL-101, and NSL-043. OncoSil’s NDL-101 is a natural product formulation which is developed as an over-the-counter product for the treatment of pain. Its NSL-043 is an oral product for the neuropathic pain. The company offers Medical’s core technology includes the application of radioactive phosphorus (P32) to patients to control tumour growth. OncoSil is headquartered in Sydney, New South Wales, Australia.<br><br>OncoSil Medical Ltd (OSL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed compa...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188276"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Stiefel Laboratories Inc - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/stiefel-laboratories-inc-pharmaceuticals-and-healthcare-deals-and-all</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Stiefel Laboratories Inc (Stiefel Laboratories), a subsidiary of GlaxoSmithKline Plc is a skincare pharmaceutical company that focuses on the skin health. The company develops products for sun care, dry skin and clear skin. It also offers research and development, manufacture, marketing and distribution of prescription medications, over-the-counter (OTC) products and signature products for the treatment of a range of dermatology conditions. Stiefel Laboratories provides treatment of a variety of dermatological ailments such as acne, atopic dermatitis, psoriasis, eczema, soriatane, seborrheic dermatitis, and various forms of dermatoses. Stiefel Laboratories is headquartered in North Carolina, the US.<br><br>Stiefel Laboratories Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partner...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188278"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[University of California San Diego - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/university-of-california-san-diego-pharmaceuticals-and-healthcare-dea</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and humanities, biological sciences, physical sciences, engineering, management, international relations and pacific studies, medicine, oceanography, pharmacy and pharmaceutical sciences, and social sciences. It offers more than 100 undergraduate majors in six disciplinary areas; social sciences, engineering, biology, science/math, arts, humanities and special/undeclared. The university provides various courses through six undergraduate colleges, five academic divisions and five graduate and professional schools. It also offers research in the areas of neuroscience, nanoscience and climate science, and provides research funding opportunities. UCSD is headquartered in La Jolla, California, the US.<br><br>University of California San Diego - Pharmaceuticals & Healthcare - Deals a...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188281"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[University of Glasgow - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/university-of-glasgow-pharmaceuticals-and-healthcare-deals-and-allian</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>University of Glasgow (UOG) is an educational and research institute that provides undergraduate, post graduate, and online programmes. It operates through its departments for law, medicine, veterinary medicine and dentistry. UOG offers courses across various disciplines that include aeronautical engineering; accountancy and finance; biochemistry; economics, electronic and software engineering among others. The university focuses its research in the areas of precision medicine, quantum technologies, nanotechnology, sensor systems, digital humanities and many other areas. UOG  also offers a wide range of high technology service supported by its research and knowledge. It operates as a member of the Russell Group of major research-led universities. UOG is headquartered in Glasgow, Scotland, the UK.<br><br>University of Glasgow - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information o...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188287"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Threshold Pharmaceuticals Inc (THLD) - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile]]></title>
      <link>https://www.leadingmarketresearch.com/threshold-pharmaceuticals-inc-thld-pharmaceuticals-and-healthcare-d</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Threshold Pharmaceuticals Inc (Threshold) is a biotechnology company that discovers and develops tumor-targeted therapies. The company’s clinical pipeline includes TH-CR-406, MAESTRO, TH-CR-413, TH-CR-408, TH-IST-4003, TH-IST-4004, TH-CR-410, TH-CR-407 and TH-IST-4001. Its products include evofosfamide, TH-4000 and [18F]-HX4. Threshold’s evofosfamide and TH-4000 are under evaluation for the treatment of a variety of tumor types. The company’s [18F]-HX4 is an in-licensed positron emission tomography imaging agent for hypoxia. Its clinical trials are used in the treatment of diseases such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer, advanced melanoma, multiple myeloma and advanced solid tumors. The company operates in Germany. Threshold is headquartered in South San Francisco, California, the US.<br><br>Threshold Pharmaceuticals Inc (THLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company&#039;s Mergers and Acquisitions (M&As), partnerships ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-188327"><span class="price">$250.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 13 Jan 2017 14:40:32 +0000</pubDate>
    </item>
  </channel>
</rss>
